Amazon recently sent shock waves through healthcare when they announced their $3.9 billion acquisitionopens in a new tab or window of One Medical. This follows its 2018 acquisition of PillPack and 2019 Amazon Care launch. With $29 billion of venture investmentopens in a new tab or window into digital health in 2021, this may seem like just another headline -- but we feel this one is different.

In placing their bet on a primary care network that delivers a hybrid of in-person and virtual care, Amazon chose a path that positions it to be a front-runner in primary care innovation.

​Read More: ​https://www.medpagetoday.com/opinion/second-opinions/100373?utm_source=Linkedin&utm_medium=Organic%20Social&utm_campaign=&utm_term=&utm_content=

Yesterday, in groundbreaking #kidneycare news, the American Heart Association issued a statement in support of home dialysis over in-center dialysis for patients with kidney and cardiovascular disease, citing cardiovascular co-morbidities and poor outcomes from thrice-weekly in-center hemodialysis, which is currently the most common therapy performed worldwide. 

Read More: ​https://www.linkedin.com/posts/outset-medical_american-heart-association-endorses-home-activity-6971854721879834624-lHCi

January Mendoza, BSN, RN, the Regional Director of Acute Dialysis at St. Francis Medical Center (SFMC) led a monumental transition when her hospital became the first in California to use a novel hemodialysis technology: #TabloDialysis.

In recognition of her essential role in the history of #TabloDialysis, January received the very first Outset Medical #PioneerAward earlier this year. She’s a shining example to others in the field of how vision, knowledge, skills and dedication can improve patient care and patient outcomes in #NephrologyNursing. Please join us in celebrating January and the leaders like her who show us what it means to be #NephNurseStrong 

Read More: ​https://www.linkedin.com/posts/outset-medical_a-pioneer-of-change-dialysis-director-january-activity-6975508883368771585-RQlp/

A new peer-to-peer review video demonstrates how effective patient-specific implants can be in treating lumbar deformities with anterior/posterior fusion. 
This video features a surgical procedure using the aprevo® interbody device. Thank you Lauren E. Stone, M.D. and Joseph A. Osorio, M.D. for advancing personalized spine surgery. Building clinical evidence is what we do at Carlsmed. To view use this link https://bit.ly/3RmbNXw. #aprevo #personalizedmedicine #getyourpowerback #patientspecific #neurosurgeon #neurosurgery

Read More: ​https://www.linkedin.com/posts/carlsmed_360-totum-alif-for-a-symptomatic-fractional-activity-6971516873561534464-xYdZ/?utm_source=share&utm_medium=member_desktop

Outset Medical (Nasdaq:OM) announced today that it has won a national contract with the U.S. Department of Veterans Affairs to sell its Tablo hemodialysis system into the department’s 106 VA hospitals.

San Jose, California–based Outset already has Tablo deployed at some VA hospitals, which overall provide dialysis for 35,000 U.S. veterans. But the new five-year contract allows VA centers to acquire consoles to send veterans home. It also expands usage in the acute setting.

​Read More: https://www.massdevice.com/outset-medical-wins-national-va-contract/

Water quality depends on many “highly fluid” variables. It is the most important component in a safe and successful hemodialysis treatment, in any setting. Here we look at a few key impacts on water that are critical in protecting patients’ health.

Read More: ​https://www.outsetmedical.com/perspective/dialysis-water-quality-filtration-treatment/

​Route 92 Medical has announced the publication of initial results from the SUMMIT NZ clinical trial—a single-arm, multicentre, prospective trial evaluating its proprietary Monopoint operating platform.

Results from the first 45 patients demonstrated that the Monopoint platform yielded an 80% first-pass effect with primary use of the HiPoint 88 (0.088-inch internal diameter [ID]) catheter, which is a super-bore catheter designed to consistently reach the proximal middle cerebral artery (MCA). The Route 92 HiPoint 88 aspiration catheter successfully reached the proximal MCA (M1 segment) in 100% of the cases attempted, as per a company press release. These results have been published online in the Journal of NeuroInterventional Surgery.

“The Monopoint operating platform with HiPoint 88 catheters delivered a step change in first-pass efficacy in the SUMMIT NZ trial, signalling clear potential for improved patient outcomes given the importance of clearing thrombus to save time and save brain,” said James Caldwell (Auckland City Hospital, Auckland, New Zealand), the paper’s first author. “The platform is designed to improve catheter deliverability, offering the advantage of greater simplicity for the operating physician to efficiently perform thrombectomy for patients.”

Read More: ​​https://neuronewsinternational.com/route-92-publishes-data-demonstrating-80-first-pass-effect-with-novel-thrombectomy-system/

SAN MATEO, Calif., June 06, 2022 -- Route 92 Medical, Inc., a private medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced the publication of initial results of the SUMMIT NZ clinical trial, a single-arm, multi-center, prospective trial evaluating the proprietary Monopoint operating platform. Results from the first 45 patients demonstrated that the Monopoint platform yielded an 80% first pass effect (FPE1) with primary use of the HiPoint™ 88 (.088in ID) catheter, a super-bore catheter designed to consistently reach the proximal middle cerebral artery (MCA). The Route 92 HiPoint 88 aspiration catheter successfully reached the proximal MCA (M1 segment) in 100% of the cases attempted. The results were published in the Journal of NeuroInterventional Surgery online2.

“The Monopoint operating platform with HiPoint 88 catheters delivered a step change in first pass efficacy in the SUMMIT NZ trial, signaling clear potential for improved patient outcomes given the importance of clearing thrombus to save time and save brain,” said Dr. James Caldwell, attending physician at Auckland City Hospital and the paper’s first author. “The platform is designed to improve catheter deliverability offering the advantage of greater simplicity for the operating physician to efficiently perform thrombectomy for patients.”

Read More: www.bakersfield.com/ap/news/route-92-medical-announces-publication-of-initial-summit-nz-clinical-trial-results/article_81496d9f-0f57-55e5-87ed-aead22a4883c.html

Chronic musculoskeletal pain has a vast global prevalence and economic burden. Conservative therapies are universally recommended but require patient engagement and self-management to be effective. This study aimed to evaluate the efficacy of a 12-week digital care program (DCP) in a large population of patients with chronic knee and back pain.
... ...
​A longitudinal observational study was conducted using a remote DCP available through a mobile app. Subjects participated in a 12-week multimodal DCP incorporating education, sensor-guided exercise therapy (ET), and behavioral health support with 1-on-1 remote health coaching. The primary outcome was pain measured by the visual analog scale (VAS). Secondary measures included engagement levels, program completion, program satisfaction, condition-specific pain measures, depression, anxiety, and work productivity.


A total of 10,264 adults with either knee (n=3796) or low back (n=6468) pain for at least three months were included in the study. Participants experienced a 68.45% average improvement in VAS pain between baseline intake and 12 weeks. In all, 73.04% (7497/10,264) participants completed the DCP into the final month.

78.60% (5893/7497) of program completers (7144/10,264, 69.60% of all participants) achieved minimally important change in pain. The number of ET sessions and coaching interactions were both positively associated with improvement in pain, suggesting that the amount of engagement influenced outcomes.

Read More: ​https://www.hingehealth.com/10000-participant-clinical-study/

SUNNYVALE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that the Centers for Medicare and Medicaid Services (CMS), through collaboration with the Society of Vascular Surgery’s Patient Safety Organization (SVS PSO) and their Vascular Quality Initiative (VQI), has expanded coverage for TCAR to include standard surgical risk patients within the VQI’s TCAR Surveillance Project (TSP). This decision is effective immediately and comes on the heels of the recent Food and Drug Administration (FDA) approval for expanded indications for the ENROUTE® Transcarotid Stent System to include patients at high risk and standard risk for adverse events from carotid endarterectomy (CEA).

“This CMS coverage expansion ensures that many more carotid artery disease patients who require treatment have the opportunity to benefit from the minimally invasive approach that our TCAR® system offers,” said Erica Rogers, President and Chief Executive Officer of Silk Road Medical. “We’re grateful to the teams at the FDA, CMS, and SVS for their valuable collaboration and partnership in recognizing the weight of real-world evidence supporting TCAR use in this expanded patient population and the necessity of working to prevent the debilitating impacts of stroke on individuals, their families, and the health system as a whole.”

Read More: ​https://www.globenewswire.com/news-release/2022/06/02/2455019/0/en/Silk-Road-Medical-Announces-Expanded-Medicare-Coverage-for-TCAR-in-Standard-Surgical-Risk-Patients.html